REVEFENACIN
Revefenacin is a long-acting muscarinic antagonist (LAMA) used as a bronchodilator to manage chronic obstructive pulmonary disease (COPD). It works by relaxing the airway muscles, making breathing easier for patients with respiratory conditions.-Used for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. -Not intended for acute relief of bronchospasms.
-Recommended Dose: 175 mcg (one vial) once daily via nebulization. -Route of Administration: Inhalation only through a standard jet nebulizer connected to an air compressor. -Missed Dose: If a dose is missed, take it as soon as possible, but do not double the next dose.
-Hypersensitivity to Revefenacin or any of its excipients. -Patients with severe hypersensitivity reactions to atropine or other muscarinic antagonists. -Not recommended for patients with severe hepatic impairment due to increased systemic exposure.
-Not for acute use in rescue therapy for bronchospasm. -Use with caution in patients with glaucoma or urinary retention, as muscarinic antagonists can worsen symptoms. -Patients with moderate hepatic impairment should be monitored for potential side effects. -Not recommended for pediatric use due to lack of safety data.
-Common: Cough, headache, dizziness, dry mouth, and nasopharyngitis. -Serious: Worsening of narrow-angle glaucoma, urinary retention, hypersensitivity reactions, and paradoxical bronchospasm.
-Avoid co-administration with other anticholinergic medications, as it may increase adverse effects. -Caution when used with CYP3A4 and CYP2D6 inhibitors, as they may increase Revefenacin exposure. -No known significant interactions with beta-agonists or corticosteroids.
